Adjuvant Bevacizumab Does Not Improve Survival in NSCLCAdjuvant Bevacizumab Does Not Improve Survival in NSCLC
The addition of bevacizumab to standard chemo regimens does not improve overall or disease-free survival in patients with resected non-small cell lung cancer (NSCLC). Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer